FDA, EMA accept Omeros ophthalmology drug applications; shares soar
This article was originally published in Scrip
Executive Summary
Shares of Omeros climbed as high as 20% on 2 October after the company said applications for its experimental ophthalmology product OMS302 were under review in the US and Europe.